TIBOR KELER - 15 Jun 2023 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
EXECUTIVE VP & CSO
Signature
/s/ Samuel B. Martin, attorney-in-fact for Tibor Keler
Issuer symbol
CLDX
Transactions as of
15 Jun 2023
Net transactions value
$0
Form type
4
Filing time
20 Jun 2023, 16:14:03 UTC
Previous filing
09 Dec 2022
Next filing
17 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option (right to buy) Award $0 +92,000 $0.000000 92,000 15 Jun 2023 Common Stock 92,000 $36.87 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
F2 25% vest on June 15, 2024 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.